<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838240</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06061</org_study_id>
    <secondary_id>EORTC-06061</secondary_id>
    <secondary_id>EU-20905</secondary_id>
    <secondary_id>2006-004912-28</secondary_id>
    <secondary_id>GIMEMA-AML-14A</secondary_id>
    <nct_id>NCT00838240</nct_id>
  </id_info>
  <brief_title>Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia</brief_title>
  <acronym>AML-14A</acronym>
  <official_title>Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as clofarabine, cytarabine, and idarubicin, work
      in different ways to stop the growth of cancer cells, either by killing the cells or by
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
      more cancer cells.

      PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
      clofarabine and to see how well it works when given together with cytarabine and idarubicin
      in treating patients with intermediate-risk or high-risk acute myeloid leukemia or high-risk
      myelodysplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the optimum dose of clofarabine in combination with cytarabine and
           idarubicin in patients with previously untreated intermediate- and high-risk acute
           myeloid leukemia or high-risk myelodysplasia. (Phase I)

        -  To determine the safety and tolerance of this regimen in order to determine the
           recommended phase II dose. (Phase I)

        -  To explore the antitumor activity of this regimen in these patients. (Phase II)

        -  To determine the activity expressed as complete remission (CR)/CR with incomplete
           hematopoietic recovery (CRi) rate following induction therapy. (Phase II)

      Secondary

        -  To determine the activity expressed as CR/CRi rate following induction (1 or 2 courses)
           and consolidation therapy. (Phase I)

        -  To determine hematopoietic recovery (platelets and neutrophils) after induction and
           consolidation therapy.

        -  To determine safety and tolerability of this regimen. (Phase II)

        -  To determine activity expressed as CR/CRi rate after consolidation therapy. (Phase II)

        -  To determine feasibility of blood CD34 harvesting after consolidation therapy. (Phase
           II)

        -  To determine disease-free and overall survival from CR/CRi. (Phase II)

      OUTLINE: This is a multicenter, phase I, dose-escalation study of clofarabine followed by an
      randomized phase II study. Patients are stratified according to center, and presence of poor
      prognostic features (WBC at diagnosis ≥ 100,000/μL vs presence of very high risk cytogenetic
      features -5/5q-, -7/7q-, presence of complex abnormalities [&gt; 3 abnormalities], 3q, t[6;9],
      or t[9;22]). Patients are randomized to 1 of 2 treatment arms.

        -  Induction therapy:

             -  Arm I: Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5,
                cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2,
                4, 6, 8, and 10.

             -  Arm II: Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also
                receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and
                10.

        -  Consolidation therapy: Patients receive cytarabine IV over 2 hours every 12 hours on
           days 1-6 and idarubicin IV over 5 minutes once daily on days 4-6.

      After completion of study therapy, patients are followed periodically for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as assessed by CTCAE v3.0 (Phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate (Phase II)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTCAE v3.0 (Phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (Phase I)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of survival from complete remission (CR)/CR with incomplete hematopoietic recovery (CRi) rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival from CR/CRi</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse and incidence of death in CR/CRi</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following by WHO criteria:

               -  Acute myeloid leukemia (AML) (≥ 20% bone marrow blasts by bone marrow aspiration
                  or biopsy)

                    -  No acute promyelocytic leukemia (M3)

                    -  All cytogenetic groups allowed, except for the following:

                         -  t(15;17)

                         -  t(8;21) or inv(16) AND a WBC count at diagnosis of &lt; 100,000/μL

                    -  Primary or secondary AML allowed, including AML after myelodysplasia (MDS)

               -  High-risk MDS (≥ 10% bone marrow blasts by bone marrow aspiration or biopsy)

          -  No chronic myelogenous leukemia in blast crisis or AML supervening a
             myeloproliferative disorder

          -  Previously untreated disease, except for ≤ 14 days of hydroxyurea

          -  No CNS leukemia

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Serum creatinine ≤ 1.0 mg/dL or glomerular filtration rate &gt; 60 mL/min

          -  AST/ALT ≤ 2.5 times upper limit of normal (ULN)

          -  ALP ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for ≥ 3 months
             after completion of study treatment

          -  No active uncontrolled infection

          -  No HIV positivity

          -  No psychological, familial, sociological, or geographical conditions precluding
             compliance with study treatment or follow up

          -  No concurrent severe uncontrolled cardiovascular disease (i.e., symptomatic congestive
             heart failure or symptomatic ischemic heart disease [NYHA class III-IV])

          -  No concurrent malignant disease

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No concurrent cytotoxic drugs or experimental therapies (e.g., antiangiogenic drugs,
             tyrosine kinase inhibitors)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roel Willemze</last_name>
    <role>Principal Investigator</role>
    <affiliation>EORTC (Phase I) - Leiden University Medical Center, NL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominik Selleslag</last_name>
    <role>Principal Investigator</role>
    <affiliation>EORTC (Phase II) - AZ Sint-Jan, BE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanna Meloni</last_name>
    <role>Principal Investigator</role>
    <affiliation>GIMEMA (Phase I &amp; II) - Universita Degli Studi &quot;La Sapienza&quot;, IT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hilde Breyssens</last_name>
    <email>hilde.breyssens@eortc.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.Z. Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominik Selleslag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dominique Bron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frédéric Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Rebro</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Boris Labar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olivier Legrand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedallera Universitaria - Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sergio Amadori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univesita Degli Studi &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giovanna Meloni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Petra Muus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>s' Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Pruijt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

